Back to Search Start Over

Theranostics in Oncology—Thriving, Now More than Ever

Authors :
Rudolf A. Werner
Takahiro Higuchi
Martin G. Pomper
Steven P. Rowe
Source :
Diagnostics, Vol 11, Iss 5, p 805 (2021)
Publication Year :
2021
Publisher :
MDPI AG, 2021.

Abstract

Tracing its roots back to the 1940s, theranostics in nuclear oncology has proved successful mainly due to the beneficial effects of image-guided therapeutic concepts for patients afflicted with a variety of different cancers. The majority of these treatments are not only characterized by substantial prolongation of progression-free and overall survival, but are also generally safe, rendering theranostic agents as an attractive treatment option in various clinical scenarios in oncology. In this Special Issue Novel Theranostic Agents, nine original articles from around the globe provide further evidence on the use of the theranostic concept for neuroendocrine neoplasm (NEN), prostate cancer (PC), meningioma, and neuroblastoma. The investigated diagnostic and therapeutic radiotracers target not only established structures, such as somatostatin receptor, prostate-specific membrane antigen or norepinephrine transporter, but also recently emerging targets such as the C-X-C motif chemokine receptor 4. Moreover, the presented original articles also combine the concept of theranostics with in-depth read-out techniques such as radiomics or novel reconstruction algorithms on pretherapeutic scans, e.g., for outcome prediction. Even 80 years after its initial clinical introduction, theranostics in oncology continues to thrive, now more than ever.

Details

Language :
English
ISSN :
20754418
Volume :
11
Issue :
5
Database :
Directory of Open Access Journals
Journal :
Diagnostics
Publication Type :
Academic Journal
Accession number :
edsdoj.3cb51e181c804d82b24e436f435d5384
Document Type :
article
Full Text :
https://doi.org/10.3390/diagnostics11050805